Product Description
Carboplatin interferes with the development of the genetic material in a cell, the DNA. This stops it from dividing into 2 new cells and kills it. Carboplatin is a chemotherapy treatment for many different types of cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/carboplatin)
Mechanisms of Action: DNA Synthesis Inhibitor, Mitosis Inhibitor, Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Malaysia, Mexico, Moldova, Montenegro, Morocco, Netherlands, New Zealand, Norway, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Anal Cancer|Bladder Cancer|Breast Cancer|Carcinosarcoma|Cervical Cancer|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Diffuse Large B-Cell Lymphoma|Endometrial Cancer|Endometrioid Carcinoma|Esophageal Cancer|Fallopian Tube Cancer|Gastrointestinal Cancer|Glioblastoma|Head and Neck Cancer|Hodgkin Lymphoma|Inflammatory Breast Cancer|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Mesothelioma|Mixed Tumor, Malignant|Mixed Tumor, Mesodermal|Mixed Tumor, Mullerian|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Nose Cancer|Other|Ovarian Cancer|Pain Unspecified|Peritoneal Cancer|Prostate Cancer|Retinoblastoma|Serous Cystadenocarcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Tobacco Use Disorder|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Unilateral Breast Cancer|Uterine Cancer
Phase 2: Anus Cancer|Brain Cancer|Carcinoma, Adenosquamous|Colorectal Cancer|Edema|Erythema|Gliosarcoma|Laryngeal Cancer|Lip Cancer|Lung Cancer|Male Breast Cancer|Mouth Cancer|Neoplastic Cells, Circulating|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Oncology Solid Tumor Unspecified|Oncology Unspecified|Oropharyngeal Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Penile Cancer|Penile Diseases|Sarcoma|Thymoma|Urogenital Cancer|Urologic Cancer
Phase 1: Epilepsy|Kidney Cancer|Kidney Diseases|Melanoma|Muscle Spasticity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04681417 |
RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT05991388 |
Glo-BNHL | P3 |
Recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2031-05-01 |
15% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT02813135 |
ESMART | P2 |
Recruiting |
Oncology Unspecified |
2031-02-01 |
2026-01-17 |
||
2018-003335-29 |
2018-003335-29 | P3 |
Active, not recruiting |
Other |
2029-10-15 |
2022-03-13 |
Treatments |
|
2024-520050-38-00 |
20240178 | P3 |
Not yet recruiting |
Nose Cancer|Small Cell Lung Cancer|Tobacco Use Disorder |
2029-07-15 |
|||
NCT06953323 |
WJB001-002-I | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2029-06-30 |
12% |
2025-08-14 |
Primary Endpoints|Start Date |
NCT07020221 |
VS-7375-101 | P2 |
Recruiting |
Gastrointestinal Cancer|Pancreatic Ductal Carcinoma|Non-Small-Cell Lung Cancer|Colorectal Cancer|Pancreatic Cancer|Adenocarcinoma |
2028-12-01 |
12% |
2026-01-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06822543 |
TROPICAL-1 | P2 |
Recruiting |
Brain Cancer|Non-Small-Cell Lung Cancer |
2028-06-30 |
2% |
2025-09-30 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT07168200 |
SHR-1316-305 | P3 |
Recruiting |
Cervical Cancer |
2028-04-01 |
46% |
2025-11-18 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06630325 |
STUDY00026643 | P2 |
Active, not recruiting |
Ovarian Cancer|Breast Cancer|Sarcoma|Pancreatic Cancer|Prostate Cancer |
2027-12-31 |
12% |
2026-01-08 |
|
NCT02876107 |
NCI-2017-00619 | P2 |
Active, not recruiting |
Breast Cancer|Erythema|Edema |
2027-10-31 |
12% |
2025-10-11 |
|
NCT05256225 |
NCI-2022-01540 | P3 |
Recruiting |
Endometrial Cancer|Clear Cell Adenocarcinoma|Mixed Tumor, Mesodermal|Mixed Tumor, Malignant|Endometrioid Carcinoma|Mixed Tumor, Mullerian |
2027-10-31 |
2026-02-05 |
Primary Endpoints|Treatments |
|
NCT05118854 |
NCI-2021-10907 | P2 |
Recruiting |
Lung Cancer |
2027-10-20 |
12% |
2025-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06232564 |
PELICAN | P2 |
Active, not recruiting |
Neuroendocrine Tumors |
2027-10-15 |
2026-01-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2022-502889-24-00 |
kp-acs-2 | P3 |
Recruiting |
Pain Unspecified |
2027-08-31 |
2025-05-02 |
Treatments |
|
NCT05733689 |
RANT-GC Trial | P1 |
Recruiting |
Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer |
2027-06-01 |
50% |
2026-03-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06351332 |
ZAP-IT | P2 |
Active, not recruiting |
Male Breast Cancer|Triple Negative Breast Cancer |
2027-03-01 |
12% |
2026-01-13 |
Primary Endpoints|Treatments|Trial Status |
NCT03997370 |
NRG-GY022 | P1 |
Recruiting |
Kidney Cancer|Kidney Diseases |
2027-02-06 |
2023-11-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT04095364 |
NRG-GY019 | P3 |
Active, not recruiting |
Serous Cystadenocarcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2027-02-01 |
2025-05-21 |
Primary Endpoints|Treatments|Trial Status |
|
NCT04574960 |
NAUTICAL | P3 |
Recruiting |
Bladder Cancer|Transitional Cell Carcinoma |
2026-12-01 |
2025-07-22 |
Primary Endpoints |
|
NCT06353906 |
PRIAM | P2 |
Recruiting |
Penile Cancer|Penile Diseases|Urogenital Cancer|Urologic Cancer|Squamous Cell Carcinoma |
2026-10-14 |
12% |
2024-08-17 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06027268 |
ToPCourT | P2 |
Active, not recruiting |
Triple Negative Breast Cancer |
2026-09-01 |
12% |
2025-10-23 |
Primary Endpoints |
NCT06727565 |
VELOCITY-HNSCC | P2 |
Active, not recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
2026-08-01 |
12% |
2026-03-03 |
|
NCT03932409 |
FIERCE | P1 |
Active, not recruiting |
Endometrial Cancer |
2026-07-01 |
50% |
2026-02-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06211023 |
SHR-A1921-301 | P3 |
Not yet recruiting |
Ovarian Cancer |
2026-06-15 |
38% |
2024-01-19 |
Primary Endpoints|Treatments |